The role of DHEA in Mental Health
Hormones play a crucial role in both physical and mental health. I doubt anyone would disagree that you must first repair the foundation before you can expect the house to be stable. When it comes to our mental and physical health, our neuroendocrine system is that very foundation.
Addressing hormonal deficiencies before initiating a standard antidepressant like a Selective Serotonin Re-uptake Inhibitor (SSRI) is not just a preference; it is a clinical imperative rooted in a deeper understanding of neurobiology and metabolic health.
One commonly overlooked hormone is dehydroepiandrosterone (DHEA), which reaches peak levels around age 25 and then steadily declines with age; by the age of 80, levels are only about 10-20% of what they are in younger adults. So, what role does DHEA play in mental health?
Let's break this down from a physiological and clinical perspective:
DHEA Itself Possesses Antidepressant Properties
First and foremost, we must recognize that DHEA is not merely an inert precursor hormone; it is a potent neurosteroid with direct psychotropic effects. Multiple studies have demonstrated its efficacy as an effective monotherapy for depression.
A landmark double-blind, randomized, placebo-controlled crossover study published in the Archives of General Psychiatry evaluated DHEA monotherapy in men and women aged 45 to 65 with midlife-onset major or minor depression. The results were compelling: six weeks of DHEA therapy was associated with a significant improvement in depression scores compared to both baseline and placebo. A remarkable 50% or greater reduction in Hamilton Depression Rating Scale scores was seen in 23 subjects on DHEA, compared to only 13 on placebo. The study concluded that "DHEA is an effective treatment for midlife-onset major and minor depression".
Therefore, the first and most straightforward reason to address a DHEA deficiency is that replenishing this hormone may, in itself, resolve the depressive symptoms, potentially rendering an antidepressant unnecessary.
DHEA's Role in Neurotransmitter Function and Brain Health
The conventional "chemical imbalance" theory posits that depression stems from a deficiency in neurotransmitters like serotonin or dopamine. While this is an oversimplification, these pathways are undeniably involved. DHEA and its metabolites play a crucial role in modulating these very systems.
Neurosteroid Actions: DHEA and its metabolites, such as allopregnanolone (derived from progesterone, which is downstream from DHEA's precursor pregnenolone), are powerful positive allosteric modulators of the GABAA receptor. This action produces anxiolytic (anti-anxiety) and calming effects, directly counteracting the anxiety that so often accompanies depression.
Neurotransmitter Modulation: Evidence suggests DHEA can influence serotonin, dopamine, and norepinephrine systems—the very targets of most antidepressant medications. For instance, DHEA has been shown to enhance dopamine release in the mesolimbic system and increase the firing rates of serotonergic neurons. By restoring the hormonal substrate, we may naturally rebalance the neurotransmitter environment that antidepressants aim to manipulate artificially.
Neuroprotection and Neurogenesis: DHEA exhibits neuroprotective effects, stimulates neurogenesis (the growth of new neurons), and promotes synaptic plasticity, particularly in the hippocampus—a brain region critical for mood regulation and often found to have reduced volume in chronic depression. Replenishing DHEA supports the brain's structural and functional integrity, creating a healthier environment for mood regulation.
The Problem with Treating Symptoms Instead of the Cause
Prescribing an antidepressant for depression caused or exacerbated by a DHEA deficiency is akin to giving pain medication for a nail in the foot without removing the nail. You are masking the symptom without addressing the root physiological dysfunction.
Furthermore, many antidepressants, particularly SSRIs, come with their own set of metabolic and hormonal consequences that can be problematic:
Sexual Dysfunction: SSRIs are notorious for causing sexual side effects, including decreased libido and anorgasmia. Conversely, DHEA therapy has been shown to improve sexual function, including desire, arousal, and satisfaction. It is clinically paradoxical to prescribe a medication known to impair sexual function when the underlying deficiency, if corrected, could improve it.
Hormonal Suppression: SSRIs have been shown in some studies to lower testosterone levels. Since DHEA is a primary precursor to testosterone in women, this creates a conflicting biochemical signal. You are giving a drug that may further suppress the androgenic pathways that are already compromised.
Insulin Resistance: Some evidence links SSRI use to increased insulin resistance. Low DHEA levels are also strongly associated with obesity, insulin resistance, and dyslipidemia. By addressing the DHEA deficiency and improving metabolic health, you may reduce the very risk factors that can contribute to and worsen depression.
Clinical Approach
When a patient presents with symptoms of depression, especially in midlife when DHEA naturally declines, a comprehensive workup is essential. This should include an assessment of DHEA-S (the sulfated, more stable form of DHEA) along with a full thyroid (especially Free T3) and sex hormone panel.
If DHEA-S levels are suboptimal, the logical first step is to replete this deficiency with a high-quality, sustained-release formulation, titrating to achieve levels seen in healthy young adults (typically 200-300 µg/dL for women and 500-600 µg/dL for men). This single intervention can improve mood, energy, cognitive function, and sexual vitality.
By optimizing the foundational hormonal milieu first, you give the body the necessary tools to regulate itself. If depressive symptoms persist after hormonal optimization, then and only then should an antidepressant be considered as an adjunctive therapy. Starting with an antidepressant in the face of a clear DHEA deficiency is, from my experience and growing research, putting the cart before the horse and often leads to polypharmacy, persistent side effects, and suboptimal clinical outcomes. We must treat the patient, not just the symptom.
- Luke Swift, DNP, APN-FPA, PMHNP-BC, ABHRT
